{"transactions":[{"id":785214,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:48:31.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1407,"price":177.62,"value":249911.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":17137,"source":{"system":"sec-edgar","filing":"0001100682-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000110068226000059/form4.xml","form_type":"4"}},{"id":785213,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:48:31.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1438,"price":177.62,"value":255417.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":15730,"source":{"system":"sec-edgar","filing":"0001100682-26-000059","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000110068226000059/form4.xml","form_type":"4"}},{"id":804398,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:10:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000119312526164253/ownership.xml","form_type":"4"}},{"id":890759,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T23:08:28.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":18055,"price":3.6,"value":64998.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000."}],"balance_after":18055,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":18055},"source":{"system":"sec-edgar","filing":"0001628280-26-010334","document":"wk-form4_1771628906.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000162828026010334/wk-form4_1771628906.xml","form_type":"4"}},{"id":1094805,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:21:32.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":29445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":36.8,"underlying":"Common Stock","underlying_shares":29445},"source":{"system":"sec-edgar","filing":"0001104659-25-065304","document":"tm2519678-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000110465925065304/tm2519678-7_4seq1.xml","form_type":"4"}},{"id":1094804,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T20:21:32.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20023,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares underlying restricted stock units (each, an \"RSU\") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a \"Parent Cash-Based RSU Award\"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065304","document":"tm2519678-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000110465925065304/tm2519678-7_4seq1.xml","form_type":"4"}},{"id":1135848,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2025-05-23T20:19:56.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":2076,"price":134.98,"value":280218.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2076,"derivative":{"exercise_price":134.98,"exercise_date":"2026-05-21","expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":2076},"source":{"system":"sec-edgar","filing":"0001127602-25-015485","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225015485/form4.xml","form_type":"4"}},{"id":1135847,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-23T20:19:56.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":815,"price":134.98,"value":110008.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 5/21/2026, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":14292,"source":{"system":"sec-edgar","filing":"0001127602-25-015485","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225015485/form4.xml","form_type":"4"}},{"id":1135846,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-23T20:19:56.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":946,"price":134.98,"value":127691.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":13477,"source":{"system":"sec-edgar","filing":"0001127602-25-015485","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225015485/form4.xml","form_type":"4"}},{"id":1147239,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T22:40:57.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":10060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 14, 2026 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":20023,"source":{"system":"sec-edgar","filing":"0001104659-25-049655","document":"tm2515271-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000110465925049655/tm2515271-1_4seq1.xml","form_type":"4"}},{"id":1147440,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2025-05-15T21:00:39.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders."}],"balance_after":28500,"derivative":{"exercise_price":0.3,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001739410-25-000080","document":"wk-form4_1747342769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000080/wk-form4_1747342769.xml","form_type":"4"}},{"id":1310819,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2025-01-06T22:07:32.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":92857,"price":0.7,"value":64999.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025."}],"balance_after":92857,"derivative":{"exercise_price":0.95,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":92857},"source":{"system":"sec-edgar","filing":"0001739410-25-000008","document":"wk-form4_1736201245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000008/wk-form4_1736201245.xml","form_type":"4"}},{"id":1446180,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-30T20:10:34.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":29445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in equal monthly installments over 36 months following July 29, 2024, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":29445,"derivative":{"exercise_price":36.8,"expiration_date":"2034-07-29","underlying":"Common Stock","underlying_shares":29445},"source":{"system":"sec-edgar","filing":"0001104659-24-083966","document":"tm2420483-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000110465924083966/tm2420483-2_4seq1.xml","form_type":"4"}},{"id":1446179,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-30T20:10:34.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":9963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer. The RSUs shall vest in three (3) equal annual installments following July 29, 2024, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":9963,"source":{"system":"sec-edgar","filing":"0001104659-24-083966","document":"tm2420483-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000110465924083966/tm2420483-2_4seq1.xml","form_type":"4"}},{"id":1516348,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-15T21:52:40.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":1311,"price":228.41,"value":299445.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The stock options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":1311,"derivative":{"exercise_price":228.41,"exercise_date":"2025-05-13","expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":1311},"source":{"system":"sec-edgar","filing":"0001127602-24-015531","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760224015531/form4.xml","form_type":"4"}},{"id":1516347,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-15T21:52:40.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":372,"price":228.41,"value":84968.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 8, 2024. The restricted stock units vest upon the earlier of 5/13/2025, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":12531,"source":{"system":"sec-edgar","filing":"0001127602-24-015531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760224015531/form4.xml","form_type":"4"}},{"id":1516346,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-15T21:52:40.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":559,"price":228.41,"value":127681.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":12159,"source":{"system":"sec-edgar","filing":"0001127602-24-015531","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760224015531/form4.xml","form_type":"4"}},{"id":1638342,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Option (Right to Buy)","published_at":"2024-02-16T23:21:36.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":216000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in 48 equal monthly installments until fully vested on February 15, 2028."}],"balance_after":216000,"derivative":{"exercise_price":1.86,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":216000},"source":{"system":"sec-edgar","filing":"0001739410-24-000019","document":"wk-form4_1708125672.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000019/wk-form4_1708125672.xml","form_type":"4"}},{"id":1837197,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-05T19:29:42.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":95,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest the earlier of July 3, 2024 and the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":11600,"source":{"system":"sec-edgar","filing":"0001127602-23-019952","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760223019952/form4.xml","form_type":"4"}},{"id":1870590,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-02T14:22:33.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest upon the earlier of 5/15/2023 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":11505,"source":{"system":"sec-edgar","filing":"0001127602-23-017435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760223017435/form4.xml","form_type":"4"}},{"id":1889718,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2023-05-17T18:43:32.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":1669,"price":192.36,"value":321048.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":1669,"derivative":{"exercise_price":192.36,"exercise_date":"2024-05-15","expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":1669},"source":{"system":"sec-edgar","filing":"0001127602-23-015850","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760223015850/form4.xml","form_type":"4"}},{"id":1889717,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-17T18:43:32.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":11167,"source":{"system":"sec-edgar","filing":"0001127602-23-015850","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760223015850/form4.xml","form_type":"4"}},{"id":2030650,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2023-02-06T22:39:38.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":214000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 6, 2027."}],"balance_after":214000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":214000},"source":{"system":"sec-edgar","filing":"0000899243-23-004074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323004074/doc4.xml","form_type":"4"}},{"id":2272426,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2022-05-13T20:57:06.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":1512,"price":222.31,"value":336132.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":1512,"derivative":{"exercise_price":222.31,"exercise_date":"2023-05-11","expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":1512},"source":{"system":"sec-edgar","filing":"0001127602-22-014473","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760222014473/form4.xml","form_type":"4"}},{"id":2272425,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-13T20:57:06.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 10, 2022. The restricted stock units vest upon the earlier of 5/11/2023, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":10503,"source":{"system":"sec-edgar","filing":"0001127602-22-014473","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760222014473/form4.xml","form_type":"4"}},{"id":2272424,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-13T20:57:06.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":10211,"source":{"system":"sec-edgar","filing":"0001127602-22-014473","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760222014473/form4.xml","form_type":"4"}},{"id":2406499,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2022-02-10T00:38:27.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is granted under the Company's 2021 Equity Incentive Plan.  The option vests in 48 equal monthly installments until fully vested on February 7, 2026."}],"balance_after":62000,"derivative":{"exercise_price":15.04,"expiration_date":"2032-02-07","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0000899243-22-005519","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322005519/doc4.xml","form_type":"4"}},{"id":2436880,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option (Right to Buy)","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter."}],"balance_after":160000,"derivative":{"exercise_price":13,"expiration_date":"2031-07-28","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436879,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Preferred Units","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":107891,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16944},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436878,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A-2 Preferred Units","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15704},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436877,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A-1 Preferred Units","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":150000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23557},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436876,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Units","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":2564999,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":380312},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436875,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Units","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":2255001,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":272609},"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436874,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-12T23:56:45.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":4496,"price":10.65,"value":47882.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive."}],"balance_after":282609,"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436873,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-12T23:56:45.000Z","date":"2022-01-10","kind":"purchase","acquired":true,"shares":5504,"price":10.1,"value":55590.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.66 to $10.65, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":278113,"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436872,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":true,"shares":436517,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company."}],"balance_after":436517,"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2436871,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-12T23:56:45.000Z","date":"2021-07-28","kind":"other","acquired":true,"shares":272609,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the \"Preferred Units\") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation."}],"balance_after":272609,"source":{"system":"sec-edgar","filing":"0000899243-22-001801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001801/doc4.xml","form_type":"4"}},{"id":2450545,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-01-04T22:06:27.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":63,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant was made in lieu of director service fees. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting."}],"balance_after":9662,"source":{"system":"sec-edgar","filing":"0001127602-22-000559","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760222000559/form4.xml","form_type":"4"}},{"id":2721342,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-10T21:29:53.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":1151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":1151,"derivative":{"exercise_price":342.55,"exercise_date":"2022-05-07","expiration_date":"2031-05-07","underlying":"Common Stock","underlying_shares":1151},"source":{"system":"sec-edgar","filing":"0001127602-21-016109","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016109/form4.xml","form_type":"4"}},{"id":2721341,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-10T21:29:53.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2021, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":9599,"source":{"system":"sec-edgar","filing":"0001127602-21-016109","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016109/form4.xml","form_type":"4"}},{"id":2721340,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-10T21:29:53.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":9380,"source":{"system":"sec-edgar","filing":"0001127602-21-016109","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016109/form4.xml","form_type":"4"}},{"id":3002800,"issuer":{"id":144989,"kind":"organization","name":"5:01 Acquisition Corp.","symbol":"FVAM"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2020-10-21T00:52:04.000Z","date":"2020-10-16","kind":"other","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors."},{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors."}],"balance_after":30000,"derivative":{"underlying":"Class A Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-055438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000120919120055438/doc4.xml","form_type":"4"}},{"id":3153070,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2020-05-12T18:14:50.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":2539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2539,"derivative":{"exercise_price":164.24,"exercise_date":"2021-05-11","expiration_date":"2030-05-11","underlying":"Common Stock","underlying_shares":2539},"source":{"system":"sec-edgar","filing":"0001127602-20-016250","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016250/form4.xml","form_type":"4"}},{"id":3153069,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-12T18:14:50.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 6, 2020.  The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":9025,"source":{"system":"sec-edgar","filing":"0001127602-20-016250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016250/form4.xml","form_type":"4"}},{"id":3153068,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-12T18:14:50.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":8568,"source":{"system":"sec-edgar","filing":"0001127602-20-016250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016250/form4.xml","form_type":"4"}},{"id":3513742,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-23T17:27:53.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of director service fees for the term commencing May 21, 2019.  The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":7827,"source":{"system":"sec-edgar","filing":"0001127602-19-019568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219019568/form4.xml","form_type":"4"}},{"id":3513741,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-23T17:27:53.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":1882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":7228,"source":{"system":"sec-edgar","filing":"0001127602-19-019568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219019568/form4.xml","form_type":"4"}},{"id":3931231,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-16T10:43:09.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of director service fees for the term commencing May 8, 2018.  The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":5346,"source":{"system":"sec-edgar","filing":"0001127602-18-017568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218017568/form4.xml","form_type":"4"}},{"id":3931230,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-16T10:43:09.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":2004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":4786,"source":{"system":"sec-edgar","filing":"0001127602-18-017568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218017568/form4.xml","form_type":"4"}},{"id":4244029,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-08-03T12:19:36.000Z","date":"2017-08-01","kind":"grant","acquired":true,"shares":607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of cash for director service fees for the term commencing July 1, 2017.  The restricted stock units vest on 8/1/2018."}],"balance_after":2782,"source":{"system":"sec-edgar","filing":"0001127602-17-024821","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217024821/form4.xml","form_type":"4"}},{"id":4244028,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-08-03T12:19:36.000Z","date":"2017-08-01","kind":"grant","acquired":true,"shares":2175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 2,175 unvested restricted stock units that vest on 8/1/2018."}],"balance_after":2175,"source":{"system":"sec-edgar","filing":"0001127602-17-024821","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217024821/form4.xml","form_type":"4"}},{"id":4415423,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-01T19:45:28.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Stock option award under 2004 Incentive Plan.  25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years."}],"balance_after":12800,"derivative":{"exercise_price":131.25,"exercise_date":"2018-02-28","expiration_date":"2027-02-28","underlying":"Common Stock, par value $.0001 per share","underlying_shares":12800},"source":{"system":"sec-edgar","filing":"0000899866-17-000057","document":"wf-form4_148841551440469.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000057/wf-form4_148841551440469.xml","form_type":"4"}},{"id":4415422,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:28.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":370,"price":132.5,"value":49025.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":50688,"source":{"system":"sec-edgar","filing":"0000899866-17-000057","document":"wf-form4_148841551440469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000057/wf-form4_148841551440469.xml","form_type":"4"}},{"id":4415421,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:28.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Award of Restricted Stock Units under the 2004 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":51058,"source":{"system":"sec-edgar","filing":"0000899866-17-000057","document":"wf-form4_148841551440469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000057/wf-form4_148841551440469.xml","form_type":"4"}},{"id":4415420,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:28.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":625,"price":131.7,"value":82312.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":38258,"source":{"system":"sec-edgar","filing":"0000899866-17-000057","document":"wf-form4_148841551440469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000057/wf-form4_148841551440469.xml","form_type":"4"}},{"id":4415419,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:28.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":860,"price":131.2,"value":112832.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":38883,"source":{"system":"sec-edgar","filing":"0000899866-17-000057","document":"wf-form4_148841551440469.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000057/wf-form4_148841551440469.xml","form_type":"4"}},{"id":4458018,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-10T18:05:20.000Z","date":"2017-02-09","kind":"sale","acquired":false,"shares":217,"price":126.84,"value":27524.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":39743,"source":{"system":"sec-edgar","filing":"0000899866-17-000037","document":"wf-form4_148676790634604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000037/wf-form4_148676790634604.xml","form_type":"4"}},{"id":4462466,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:39:10.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":18,"price":126.88,"value":2283.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":39960,"source":{"system":"sec-edgar","filing":"0000899866-17-000025","document":"wf-form4_148658993769140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000025/wf-form4_148658993769140.xml","form_type":"4"}},{"id":4462465,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Global Head of R&D"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:39:10.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":2710,"price":125.69,"value":340619.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":39978,"source":{"system":"sec-edgar","filing":"0000899866-17-000025","document":"wf-form4_148658993769140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000025/wf-form4_148658993769140.xml","form_type":"4"}},{"id":517724,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-05-18T19:55:39.000Z","date":"2010-05-14","kind":"grant","acquired":true,"shares":236,"price":16.2,"value":3823.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":10637,"derivative":{"underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0001225208-10-013292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810013292/doc4.xml","form_type":"4"}},{"id":519336,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-05-03T19:43:41.000Z","date":"2010-04-30","kind":"grant","acquired":true,"shares":117,"price":16.72,"value":1956.24,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":10401,"derivative":{"underlying":"Common Stock","underlying_shares":117},"source":{"system":"sec-edgar","filing":"0001225208-10-011619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810011619/doc4.xml","form_type":"4"}},{"id":519908,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-04-16T21:34:24.000Z","date":"2010-04-15","kind":"grant","acquired":true,"shares":115,"price":16.99,"value":1953.85,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":10284,"derivative":{"underlying":"Common Stock","underlying_shares":115},"source":{"system":"sec-edgar","filing":"0001225208-10-010496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810010496/doc4.xml","form_type":"4"}},{"id":520617,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-04-01T22:40:39.000Z","date":"2010-03-31","kind":"grant","acquired":true,"shares":111,"price":17.15,"value":1903.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":10169,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001225208-10-009468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810009468/doc4.xml","form_type":"4"}},{"id":520837,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-03-17T13:25:29.000Z","date":"2010-03-15","kind":"grant","acquired":true,"shares":2718,"price":17.26,"value":46912.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":10058,"derivative":{"underlying":"Common Stock","underlying_shares":2718},"source":{"system":"sec-edgar","filing":"0001225208-10-008383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810008383/doc4.xml","form_type":"4"}},{"id":522147,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Stock Appreciation Rights","published_at":"2010-03-02T02:01:36.000Z","date":"2010-02-25","kind":"grant","acquired":true,"shares":163288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant."}],"balance_after":163288,"derivative":{"exercise_price":17.69,"exercise_date":"2015-02-25","expiration_date":"2015-02-25","underlying":"Common Stock","underlying_shares":163288},"source":{"system":"sec-edgar","filing":"0001225208-10-006399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810006399/doc4.xml","form_type":"4"}},{"id":522146,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2010-03-02T02:01:36.000Z","date":"2010-02-25","kind":"tax_withholding","acquired":false,"shares":1127,"price":17.69,"value":19936.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance-Contingent Shares."}],"balance_after":375044,"source":{"system":"sec-edgar","filing":"0001225208-10-006399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810006399/doc4.xml","form_type":"4"}},{"id":522145,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2010-03-02T02:01:36.000Z","date":"2010-02-25","kind":"grant","acquired":true,"shares":3471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported transaction constitutes the earn-out of Performance-Contingent Shares."}],"balance_after":376171,"source":{"system":"sec-edgar","filing":"0001225208-10-006399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810006399/doc4.xml","form_type":"4"}},{"id":522144,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2010-03-02T02:01:36.000Z","date":"2010-02-25","kind":"grant","acquired":true,"shares":66017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements."}],"balance_after":372700,"source":{"system":"sec-edgar","filing":"0001225208-10-006399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810006399/doc4.xml","form_type":"4"}},{"id":525072,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2010-01-04T21:12:15.000Z","date":"2009-12-31","kind":"grant","acquired":true,"shares":104,"price":18.19,"value":1891.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":7265,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":104},"source":{"system":"sec-edgar","filing":"0001225208-10-000246","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520810000246/doc4.xml","form_type":"4"}},{"id":525408,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-12-16T22:08:24.000Z","date":"2009-12-15","kind":"grant","acquired":true,"shares":103,"price":18.29,"value":1883.87,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":7161,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":103},"source":{"system":"sec-edgar","filing":"0001225208-09-024591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520809024591/doc4.xml","form_type":"4"}},{"id":526044,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-12-01T21:45:19.000Z","date":"2009-11-30","kind":"grant","acquired":true,"shares":102,"price":18.17,"value":1853.34,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":7058,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":102},"source":{"system":"sec-edgar","filing":"0001225208-09-023535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520809023535/doc4.xml","form_type":"4"}},{"id":526666,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-11-17T00:35:58.000Z","date":"2009-11-13","kind":"grant","acquired":true,"shares":169,"price":17.59,"value":2972.71,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6956,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":169},"source":{"system":"sec-edgar","filing":"0001225208-09-022353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520809022353/doc4.xml","form_type":"4"}},{"id":527204,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"officer":true,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-11-03T21:37:48.000Z","date":"2009-10-30","kind":"grant","acquired":true,"shares":112,"price":17.03,"value":1907.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6787,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":112},"source":{"system":"sec-edgar","filing":"0001225208-09-021512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000122520809021512/doc4.xml","form_type":"4"}},{"id":527565,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-10-16T20:45:13.000Z","date":"2009-10-15","kind":"grant","acquired":true,"shares":106,"price":17.66,"value":1871.96,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6675,"derivative":{"underlying":"Common Stock","underlying_shares":106},"source":{"system":"sec-edgar","filing":"0000078003-09-000222","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000222/primary_doc.xml","form_type":"4"}},{"id":527906,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-10-01T17:25:45.000Z","date":"2009-09-30","kind":"grant","acquired":true,"shares":115,"price":16.55,"value":1903.25,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6569,"derivative":{"underlying":"Common Stock","underlying_shares":115},"source":{"system":"sec-edgar","filing":"0000078003-09-000209","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000209/primary_doc.xml","form_type":"4"}},{"id":528093,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-09-16T23:23:26.000Z","date":"2009-09-15","kind":"grant","acquired":true,"shares":119,"price":16.21,"value":1928.99,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6454,"derivative":{"underlying":"Common Stock","underlying_shares":119},"source":{"system":"sec-edgar","filing":"0000078003-09-000194","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000194/primary_doc.xml","form_type":"4"}},{"id":528338,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-09-01T21:30:17.000Z","date":"2009-08-31","kind":"grant","acquired":true,"shares":109,"price":16.7,"value":1820.3,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6335,"derivative":{"underlying":"Common Stock","underlying_shares":109},"source":{"system":"sec-edgar","filing":"0000078003-09-000184","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000184/primary_doc.xml","form_type":"4"}},{"id":528651,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-08-18T15:31:39.000Z","date":"2009-08-14","kind":"grant","acquired":true,"shares":182,"price":15.77,"value":2870.14,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6226,"derivative":{"underlying":"Common Stock","underlying_shares":182},"source":{"system":"sec-edgar","filing":"0000078003-09-000174","document":"mac2117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000174/mac2117.xml","form_type":"4"}},{"id":529086,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-08-04T15:10:39.000Z","date":"2009-07-31","kind":"grant","acquired":true,"shares":119,"price":15.93,"value":1895.67,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":6044,"derivative":{"underlying":"Common Stock","underlying_shares":119},"source":{"system":"sec-edgar","filing":"0000078003-09-000166","document":"mac2108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000166/mac2108.xml","form_type":"4"}},{"id":529507,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-07-16T19:56:47.000Z","date":"2009-07-15","kind":"grant","acquired":true,"shares":126,"price":15.02,"value":1892.52,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5925,"derivative":{"underlying":"Common Stock","underlying_shares":126},"source":{"system":"sec-edgar","filing":"0000078003-09-000154","document":"mac2100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000154/mac2100.xml","form_type":"4"}},{"id":529778,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-07-01T20:24:48.000Z","date":"2009-06-30","kind":"grant","acquired":true,"shares":124,"price":15,"value":1860.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5799,"derivative":{"underlying":"Common Stock","underlying_shares":124},"source":{"system":"sec-edgar","filing":"0000078003-09-000139","document":"mac2082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000139/mac2082.xml","form_type":"4"}},{"id":530002,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-06-16T19:55:16.000Z","date":"2009-06-15","kind":"grant","acquired":true,"shares":136,"price":14.13,"value":1921.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5675,"derivative":{"underlying":"Common Stock","underlying_shares":136},"source":{"system":"sec-edgar","filing":"0000078003-09-000127","document":"mac2066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000127/mac2066.xml","form_type":"4"}},{"id":530309,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-06-02T13:58:10.000Z","date":"2009-05-29","kind":"grant","acquired":true,"shares":125,"price":15.19,"value":1898.75,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5539,"derivative":{"underlying":"Common Stock","underlying_shares":125},"source":{"system":"sec-edgar","filing":"0000078003-09-000116","document":"mac2052.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000116/mac2052.xml","form_type":"4"}},{"id":530650,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-05-18T20:53:38.000Z","date":"2009-05-15","kind":"grant","acquired":true,"shares":180,"price":15.01,"value":2701.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5414,"derivative":{"underlying":"Common Stock","underlying_shares":180},"source":{"system":"sec-edgar","filing":"0000078003-09-000106","document":"mac2041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000106/mac2041.xml","form_type":"4"}},{"id":531212,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-05-01T18:00:56.000Z","date":"2009-04-30","kind":"grant","acquired":true,"shares":141,"price":13.36,"value":1883.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5234,"derivative":{"underlying":"Common Stock","underlying_shares":141},"source":{"system":"sec-edgar","filing":"0000078003-09-000096","document":"mac2031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000096/mac2031.xml","form_type":"4"}},{"id":531474,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-04-16T21:20:57.000Z","date":"2009-04-15","kind":"grant","acquired":true,"shares":138,"price":13.86,"value":1912.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":5093,"derivative":{"underlying":"Common Stock","underlying_shares":138},"source":{"system":"sec-edgar","filing":"0000078003-09-000073","document":"mac2009.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000073/mac2009.xml","form_type":"4"}},{"id":531754,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-04-01T20:06:30.000Z","date":"2009-03-31","kind":"grant","acquired":true,"shares":148,"price":13.62,"value":2015.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":4955,"derivative":{"underlying":"Common Stock","underlying_shares":148},"source":{"system":"sec-edgar","filing":"0000078003-09-000060","document":"mac1999.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000060/mac1999.xml","form_type":"4"}},{"id":531953,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-03-16T20:50:14.000Z","date":"2009-03-13","kind":"grant","acquired":true,"shares":2889,"price":14.54,"value":42006.06,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":4807,"derivative":{"underlying":"Common Stock","underlying_shares":2889},"source":{"system":"sec-edgar","filing":"0000078003-09-000047","document":"mac1985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000047/mac1985.xml","form_type":"4"}},{"id":532424,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Stock Appreciation Rights","published_at":"2009-03-03T22:00:18.000Z","date":"2009-02-26","kind":"grant","acquired":true,"shares":195896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Amendment filed to correct the number of stock appreciation rights granted on February 26, 2009."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant"}],"balance_after":195896,"derivative":{"exercise_price":12.7,"exercise_date":"2014-02-26","expiration_date":"2014-02-26","underlying":"Common Stock","underlying_shares":195896},"source":{"system":"sec-edgar","filing":"0000078003-09-000041","document":"mac1978.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000041/mac1978.xml","form_type":"4/A","original_submission_date":"2009-03-02"}},{"id":532559,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Stock Appreciation Rights","published_at":"2009-03-02T23:27:11.000Z","date":"2009-02-26","kind":"grant","acquired":true,"shares":83955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant"}],"balance_after":83955,"derivative":{"exercise_price":12.7,"exercise_date":"2014-02-26","expiration_date":"2014-02-26","underlying":"Common Stock","underlying_shares":83955},"source":{"system":"sec-edgar","filing":"0000078003-09-000033","document":"mac1968.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000033/mac1968.xml","form_type":"4"}},{"id":532558,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units","published_at":"2009-03-02T23:27:11.000Z","date":"2009-02-26","kind":"grant","acquired":true,"shares":4234,"price":12.7,"value":53771.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Units represent incentive compensation that has been deferred. Units will be settled in cash following separation from service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Units represent incentive compensation that has been deferred. Units will be settled in cash following separation from service."}],"balance_after":4234,"derivative":{"underlying":"Common Stock","underlying_shares":4234},"source":{"system":"sec-edgar","filing":"0000078003-09-000033","document":"mac1968.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000033/mac1968.xml","form_type":"4"}},{"id":532557,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2009-03-02T23:27:11.000Z","date":"2009-02-26","kind":"tax_withholding","acquired":false,"shares":5837,"price":12.7,"value":74129.9,"ownership":{"direct":true},"balance_after":297581,"source":{"system":"sec-edgar","filing":"0000078003-09-000033","document":"mac1968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000033/mac1968.xml","form_type":"4"}},{"id":532556,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2009-03-02T23:27:11.000Z","date":"2009-02-26","kind":"grant","acquired":true,"shares":37114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported transaction constitutes the earn-out of Performance-Contingent Shares and Performance Shares."}],"balance_after":303418,"source":{"system":"sec-edgar","filing":"0000078003-09-000033","document":"mac1968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000033/mac1968.xml","form_type":"4"}},{"id":532555,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2009-03-02T23:27:11.000Z","date":"2009-02-26","kind":"grant","acquired":true,"shares":99868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction constitutes the grant of restricted stock units."}],"balance_after":266304,"source":{"system":"sec-edgar","filing":"0000078003-09-000033","document":"mac1968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000033/mac1968.xml","form_type":"4"}},{"id":534859,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2009-01-05T12:58:26.000Z","date":"2008-12-31","kind":"grant","acquired":true,"shares":95,"price":17.71,"value":1682.45,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1870,"derivative":{"underlying":"Common Stock","underlying_shares":95},"source":{"system":"sec-edgar","filing":"0000078003-09-000007","document":"mac1948.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800309000007/mac1948.xml","form_type":"4"}},{"id":535129,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2008-12-16T23:51:24.000Z","date":"2008-12-15","kind":"grant","acquired":true,"shares":101,"price":16.63,"value":1679.63,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1775,"derivative":{"underlying":"Common Stock","underlying_shares":101},"source":{"system":"sec-edgar","filing":"0000078003-08-000314","document":"mac1937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800308000314/mac1937.xml","form_type":"4"}},{"id":535406,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2008-12-01T22:25:09.000Z","date":"2008-11-26","kind":"grant","acquired":true,"shares":105,"price":16.07,"value":1687.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1674,"derivative":{"underlying":"Common Stock","underlying_shares":105},"source":{"system":"sec-edgar","filing":"0000078003-08-000303","document":"mac1926.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800308000303/mac1926.xml","form_type":"4"}},{"id":535613,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2008-11-17T21:44:34.000Z","date":"2008-11-14","kind":"grant","acquired":true,"shares":131,"price":16.28,"value":2132.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1569,"derivative":{"underlying":"Common Stock","underlying_shares":131},"source":{"system":"sec-edgar","filing":"0000078003-08-000292","document":"mac1915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800308000292/mac1915.xml","form_type":"4"}},{"id":535905,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2008-11-03T19:53:31.000Z","date":"2008-10-31","kind":"grant","acquired":true,"shares":95,"price":17.71,"value":1682.45,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1438,"derivative":{"underlying":"Common Stock","underlying_shares":95},"source":{"system":"sec-edgar","filing":"0000078003-08-000274","document":"mac1904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800308000274/mac1904.xml","form_type":"4"}},{"id":536069,"issuer":{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Phantom Stock Units SSP","published_at":"2008-10-16T18:51:28.000Z","date":"2008-10-15","kind":"grant","acquired":true,"shares":104,"price":16.27,"value":1692.08,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit represents one phantom share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."}],"balance_after":1343,"derivative":{"underlying":"Common Stock","underlying_shares":104},"source":{"system":"sec-edgar","filing":"0000078003-08-000266","document":"mac1892.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800308000266/mac1892.xml","form_type":"4"}}],"next_cursor":"2008-10-16T18:51:28.000000Z,536069"}